Quaker BioVentures - Portfolio Companies

Portfolio Companies

(NASDAQ: FOLD) Cranbury, NJ		Amicus is a publicly traded biopharmaceutical company developing small molecule, orally active drugs to treat a range of human genetic diseases including lysosomal storage disorders. Amicus’ paradigm-shifting approach uses pharmacological chaperones to selectively bind and “rescue” misfolded target proteins to restore proper conformation, trafficking, and biological activity.

North Charleston, SC		Argolyn is a privately held biopharmaceutical company dedicated to discovering and developing novel peptide drug candidates to treat psychosis, pain, and other diseases/disorders. Argolyn’s product candidates are being developed using a proprietary amino acid analog substitution technology which enables the rapid and efficient discovery of novel, peptide-based drug candidates.

Pittsboro, NC		Biolex is developing a revolutionary system for the recombinant production of therapeutic proteins. The company’s business model has two major components: 1) development of proprietary “Biolex Proteins” and 2) co-development projects with other biopharma companies. The lead Biolex Protein is in Phase 2 trials for Hepatitis C.

Acquired by Pfizer in February 2007		BioRexis is developing novel protein and peptide drugs with long half-lives. The company couples its proprietary protein engineering technology with a modified form of transferrin, a human serum protein, to enhance efficacy and safety of therapeutic proteins and peptides, initially for diabetes. The company was acquired by Pfizer in February 2007.

Princeton, NJ		Celator is a biopharmaceutical company developing new and more effective therapies to treat cancer. The company's Combiplex technology identifies ratios of synergistic drug combinations in vitro and fixes these ratios in drug carriers so they remain true in vivo. Proprietary products are in Phase 1 and 2 trials for various forms of cancer.

Philadelphia, PA		Cellatope is a diagnostics company developing an early identification and monitoring solution for inflammatory diseases such as lupus. Cellatope's platform, CB-CAPs (Cell-Bound Complement Activation Products), allows for the accurate monitoring of disease activity.

Conshohocken, PA		Diasome is a biopharmaceutical company focused on the development and commercialization of a novel drug targeting system for the improved treatment of diabetes. Clinical trials with Diasome’s patented nanotechnology, known as Hepatocyte Directed Vesicles, have demonstrated improved blood glucose control and a decreased risk of hypoglycemia in diabetic patients.

(NASDAQ: DSCO) Warrington, PA		Discovery is a publicly traded biopharmaceutical company developing a proprietary synthetic lung surfactant technology. The precision-engineered surfactant has significant advantages over currently marketed surfactants, and is awaiting FDA approval.

Bridgewater, NJ		EKR is an emerging specialty pharmaceutical company focused on the acute care setting. EKR has licensed two FDA approved products, Gelclair and DepoDur. Gelclair is approved for the treatment of oral mucositis, an often a dose limiting side effect of various cancer therapies. EKR’s second product, DepoDur is approved for the management of post-operative pain with advantages over other post-operative analgesics for selected orthopedic and abdominal surgical procedures.

West Conshohocken, PA		Immune Control, a biopharmaceutical company, discovered that blocking certain serotonin receptors initiates apoptosis, or programmed cell death, of activated lymphocytes. The company is sponsoring early clinical trials in both multiple myeloma and psoriasis.

Morrisville, NC		Kolis Scientific is a clinical stage company developing a novel, office-based medical device to treat dry eye syndrome.

Acquired by Walgreen Co. in July 2006		Medmark is a specialty pharmaceutical distributor, focused on high-cost injectables and infusibles that require special handling and strict adherence to prescribed treatment protocols. The company was acquired by Walgreens in July 2006.

Malvern, PA		Neotropix is a biotechnology company developing proprietary oncolytic viruses to treat cancer. The systemically administered therapy was spun-out of Novartis, and is now in early clinical trials, focusing on patients with small cell lung cancer.

Malvern, PA		Neuronetics is a medical device company developing and commercializing noninvasive therapies to treat psychiatric and neurological disorders. The company’s lead product, NeuroStar, uses Transcranial Magnetic Stimulation (TMS) to non-invasively treat patients with depression. Clinical trials have demonstrated that the product is safe and effective, and it is awaiting FDA approval.

Bristol, PA		NitricBio is a clinical stage company focused on the development of a proprietary and patented drug/device technology for the treatment of chronic wounds and other topical disorders such as skin infections and psoriasis. ViaNOx™ delivers gaseous nitric oxide to topical wounds, and impacts healing with potent anti-inflammatory and anti-microbial properties.

Horsham, PA		Nucleonics is a biotechnology company with a leading position in a new class of therapeutic agents called expressed interfering RNA (eRNAi). eRNAi has several potential advantages over other RNAi technologies such as lower cost, less toxicity, and more rapid clinical development. The company is targeting chronic viral diseases, cancer and inflammatory diseases.

Conshohocken, PA		NuPathe is a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases. The company’s lead product, NP101, is a transdermal patch that delivers sumatriptan to treat migraine by addressing two well-recognized problems in migraine treatment, nausea/vomiting and recurrent headache, while maintaining rapid onset.

Branford, CT		Optherion is a biopharmaceutical company developing novel therapeutics and diagnostics for the dry form of age related macular degeneration (AMD) and membranoproliferative glomerulonephritis type II (MPGN-II). The company is targeting diseases modulated by Complement Factor H (CFH). CFH is recognized as a key factor impacting dry AMD, which is the leading cause of irreversible visual dysfunction in America. Optherion is in preclinical development.

Pittsburgh, PA		Precision is a diagnostics service company dedicated to the personalization of cancer therapy. Precision provides treatment support tools to physicians, enabling customized and predictive treatment decisions for each cancer patient using a proprietary cell-based assay that provides direct insight into which chemotherapy regimens may be most effective.

Malvern, PA		Protez is developing small molecule antibiotics to address increasing bacterial resistance and chronic or recurrent infections. Protez’s lead compound, PZ-601, is a potent injectable antibiotic with a unique broad spectrum of activity against both drug resistant gram positive (MRSA, VRSA, VRE) and many gram negative pathogens.

Morrisville, NC		Regado is a biopharmaceutical company developing antidote-controlled therapeutics via rational design of drug-antidote pairs. The drug is a modified RNA-based aptamer and the antidote is an oligonucleotide complementary to the aptamer. Regado is initially focusing on the acute care antithrombotics market. Its antidote-controlled anticoagulant has completed extensive Phase 1 trials.

Horsham, PA		TargetRx is an emerging growth company revolutionizing the way pharmaceutical companies apply marketing information to their operations. TargetRx’s core technology is a proprietary database of "attitudinal" information that provides insight on why physicians prescribe pharmaceutical products. The company’s product informs clients of how they can take action to accentuate or blunt prescribing trends.

East Norriton, PA		Tengion is a leader in the field of regenerative medicine. The company is developing new human tissues and organs (neo-tissues and neo-organs) that are derived from a patient's own cells. Its lead product, an autologous neo-bladder, is in Phase 1/2 trials for patients with spina bifida and spinal cord injury.

Malvern, PA		TetraLogic is a biopharmaceutical company developing novel, targeted drugs to treat cancer. The company’s Smac-mimetic candidates regulate the apoptosis (programmed cell death) pathway by unblocking the pathway to kill cancer cells.

Monmouth Jct., NJ		Transave is a privately held biopharmaceutical company developing an inhaled therapeutic, Arikace, with a targeted initial indication to treat pseudomonas aeruginosa lung infections in cystic fibrosis and bronchiectasis patients. Arikace is a once daily inhaled therapeutic of a liposomal formulation of amikacin, an FDA approved antibiotic, that has the potential to reduce treatment burden, increase efficacy, and decreased safety/tolerability issues.

West Conshohocken, PA		Transport is developing a proprietary drug/device platform for the treatment of dermatological diseases. The company’s lead product uses patented ionotophoretic technology for the rapid treatment of herpes labialis (cold sores). Phase 2 trials are ongoing.

Durham, NC		Tranzyme is a biopharmaceutical company developing unique small molecule therapeutics originating from its proprietary chemistry platform. The lead product, TZP-101, is a ghrelin receptor agonist that completed Phase 1 trials for GI motility disorders such as post-operative ileus and acute gastroparesis. Tranzyme is also developing therapeutics for chronic gastroparesis, obesity and functional GI disorders.

(AMEX: YMI, TSX: YM) Berwyn, PA		YM Biosciences acquired Eximias Pharmaceutical Corp. in 2006, and Eximias is now a wholly-owned subsidiary of YM operating as YM BioSciences USA. YM is an oncology focused company with a portfolio of late stage clinical assets.